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Reactive oxygen speciesThree novel pyrimidinylhydrazones substituted at either the aromatic moiety or at the imine carbon atomwere
synthesized and characterized by standard analytical methods. All compounds were found to be toxic in the
micro- to submicromolar range against a diverse panel of cancer cell lines including multidrug resistant (MDR)
derivatives expressing P-glycoprotein (Pgp). UV–visible spectrophotometry experiments demonstrated that
the most active compound (3) forms highly stable complexes with iron(III) and copper(II) in a wide pH range
with a stronger preference towards iron(III). The redox activity of the iron and copper complexes of ligand 3
was investigated using cyclic voltammetry and was tested with cellular reductants. The impact of reactive
oxygen species (ROS) on the mechanism of toxicity was assessed using the ROS-sensitive cell permeable dye
2′,7′-dichloroﬂuorescin diacetate (DCFDA). Our results demonstrate that the studied pyrimidinylhydrazones
form redox-active iron and copper complexes that are capable of producing intracellular ROS, which might
lead to cellular damage and cell death in cancer cells regardless of their resistance status.
© 2014 Published by Elsevier Inc.1. Introduction
The cellular homeostasis of metals is tightly regulated. As a result,
only a minor fraction of the intracellular pools is freely available, and
the majority of metal ions are bound to storage proteins or enzymes
that utilize them as cofactors or as structural support elements [1,2].
It is estimated that at least one third of the human proteome consists
of metalloproteins, many of which have been associated with various
pathological conditions including infectious, cardiovascular and
neurodegenerative diseases [3,4]. As compounds that can directly
target the metal ion cofactors of metalloproteins are expected to
have a signiﬁcant biological effect, the development of chelators is
a promising strategy in medicinal chemistry. Chelators have been
traditionally used for the treatment of metal overload and diseases re-
lated to imbalanced metal homeostasis including hemochromatosis,
β-thalassemia, and Alzheimer's or Parkinson's diseases [5,6]. Several
studies have described the deregulation of iron homeostasis in cancer,
suggesting that the alteredmetal homeostasis of cancer cells represents
a vulnerability that can be targeted by chelation strategies [7,8].
Cancer cells increasingly rely on iron due to the crucial role of
metalloproteins in proliferation. Since metal homeostasis is tightlyyedy),linked to the regulation of the intracellular redox balance, anticancer
metal complexes can also target cancer cells by the formation
of redox active complexes giving rise to reactive oxygen species
(ROS) [5,8].
Examples of chelators with antitumor potential include aroyl- and
arylhydrazones, and variously substituted thiosemicarbazones [9–15].
The proposed mechanism of action of these antibacterial and anti-
cancer compounds is linked to the inhibition of the iron-requiring
enzyme ribonucleotide reductase (RR) [5,8], the rate determining
enzyme supplying deoxyribonucleotides for DNA synthesis [16].
The mammalian enzyme consists of two subunits: R1 harbors the
catalytically active center; R2 contains a tyrosyl radical and a diiron
center [17]. Compounds targeting RR include antimetabolites such
as gemcitabine, scavengers of the tyrosyl radical (hydroxyurea),
gallium(III) complexes and various chelators. Triapine, a tridentate
α-N-pyridyl thiosemicarbazone is a potent RR inhibitor currently
undergoing phase I and II clinical trials [18–20]. Unfortunately,
Triapine is subject to multidrug resistance (MDR), as it is
recognized by the ATP-binding cassette (ABC) transporter
P-glycoprotein (Pgp/ABCB1) [21]. MDR is a major obstacle in
the treatment of cancer. Hence, there is an urgent need for new
strategies aiming to overcome MDR [22]. Numerous metal complexes
have been developed with the aim of bypassing or even targeting
MDR, while minimizing the side effects of clinically used platinum
complexes [23].
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ized by antibacterial, antimycobacterial, analgesic and anticancer ac-
tivities [12,13,24,25]. Several pyridyl- and pyrimidinylhydrazones
were reported to be effective against multidrug resistant strains of
leprosy and tuberculosis [13,26] and cancer cell lines [14]. Compared
to closely related derivatives, pyrimidinylhydrazones with 4′-methoxy-
and 5-ethyl-substituents have been suggested to show a higher and
broader activity against Mycobacteria [15]. In the case of structurally
related aroylhydrazones the introduction of an additional pyridine
ring at the imine carbon of pyridylcarboxaldehyde isonicotinoyl
hydrazone (PCIH) led to increased iron chelation and enhanced antitu-
mor activity [11]. Here we have investigated the antitumor activity of
arylhydrazones from the pyrimidinyl type. Since the α-position to the
hydrazine moiety was shown to inﬂuence toxicity, we synthesized a
derivative with methylation at the imine carbon. The ligands were
tested for their in vitro antiproliferative activity in six human cancer
cell lines. We show that three donor nitrogen atoms enable the
formation of stable and redox-active complexes with iron(III) and
copper(II). UV–visible (UV–Vis) spectrophotometric titrations were
applied to investigate speciation in aqueous solution, and cyclic
voltammetry was used to characterize the redox activity of the
complexes. The impact of metal ions on the antiproliferative activity
and the formation of ROS were also investigated.
2. Materials and methods
2.1. Chemicals
Chemicals used for synthesis were procured from Acros Organics
(Geel, Belgium), Alfa Aesar (Karlsruhe, Germany), Sigma-Aldrich
(Schnelldorf, Germany) or TCI (Eschborn, Germany) and used without
further puriﬁcation. Column chromatography was performed using
Silica gel 60 (40–63 μm, Merck, Darmstadt, Germany) as stationary
phase. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), N-acetylcysteine (NAC) and 2′,7′-dichloroﬂuorescin diacetate
(DCFDA) were purchased from ABCR Chemicals (Karlsruhe, Germany),
TCI (Eschborn, Germany) and Sigma-Aldrich (Schnelldorf, Germany),
respectively. The Pgp inhibitor WK-X-24 (XR9577) was used from
prior synthesized stocks (Laboratory of Prof. M.Wiese, Bonn university,
Germany) [27], Tariquidar was a kind gift from Dr. Susan Bates (NCI).
Solid KOH, and tetrabutylammoniumchloride (TBACl), ferrocene, uracil,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2-(N-
morpholino)ethanesulfonic acid (MES), ascorbic acid (ASC) and gluta-
thione (GSH) were purchased from Sigma-Aldrich and HCl, KCl, CuCl2,
FeCl3 were Reanal products (Budapest, Hungary). Fe(III) and Cu(II)
stock solutions were prepared by dissolving the appropriate amount
of the metal chlorides in known amounts of HCl. Their concentrations
were determined by complexometry via the EDTA complexes. Accurate
strong acid content of the metal stock solutions were determined by
pH-potentiometric titrations. Ligand 3 was dissolved in pure DMSO to
obtain the stock solution (0.01 M).
2.2. Synthesis and physical measurements
The ligands were prepared following the synthetic route suggested
by Seydel et al. with minor modiﬁcations [15]. 1H NMR and 13C NMR
spectrawere obtained on either a Bruker Advance 300 or 500 spectrom-
eter, respectively. DMSO-d6 or CDCl3 were used as solvents. Standard
pulse programs were applied. Chemical shifts are expressed in ppm
values using the residual solvent peaks as internal standards (DMSO-
d6 2.50; 39.52 ppm or CDCl3 7.26; 77.16 ppm) [28]. 13C NMR signals
were assigned with the aid of attached proton test (APT) spectra.
Elemental analyses of the ﬁnal products were performed on a Vario EL
elemental analyzer (Hanau, Germany). The values for carbon, nitrogen
and hydrogen are given in percentage. Electrospray ionization-mass
spectrometry (ESI-MS) measurements for the characterization of theﬁnal products were carried out with a Waters Q-TOF Premier
instrument (Waters Kft., Hungary) operating in positive ion mode;
the samples were dissolved in methanol.
2.2.1. 4-Chloro-6-methoxypyrimidine
To a cooled solution (−10 °C) of 4,6-dichloropyrimidine (1193-21-
1, 5 g, 33.56 mmol) in dry methanol, one equivalent of sodium hydride
(titrated solution in drymethanol)was added, the solutionwas allowed
to warm to room temperature and react for 48 h (depicted in step a
of Scheme 1). The solvent was removed; the crude product was
dissolved in brine, extracted with CHCl3, and was used without
further puriﬁcation. 1H NMR (500 MHz, DMSO-d6): δ = 8.68
(d, 5J(H,H) = 0.8 Hz, 1H, H-2), 7.18 (d, 5J(H,H) = 0.9 Hz, 1H, H-5),
3.96 (s, 3H, OCH3).
2.2.2. 4-Hydrazinyl-6-methoxypyrimidine
To a solution of the 4-chloro-6-methoxypyrimidine, obtained as de-
scribed in Section 2.2.1 (2.5 g crude product), in methanol an aqueous
solution of hydrazine (80%, 6.1 mL) was added and reﬂuxed (see step
b of Scheme 1). After evaporation of the solvent, the aqueous solution
of the crude product was alkalized with NaOH and extracted with
methylene chloride to give the product as an ochre powder in
60% yield. 1H NMR (500 MHz, CDCl3): δ = 8.26 (s, 1H, H-2), 6.42
(bs, 1H, NH), 6.07 (s, H-5), 3.92 (s, 3H, OCH3), 3.42 (bs, 2H, NH2). 13C
NMR (126 MHz, CDCl3): δ= 170.72 (C-6), 167.17 (C-4), 157.68 (C-2),
84.90 (C-5), 53.87 (OCH3).
2.2.3. 5-Ethyl-2-methyl-pyridine-N-oxide
35mL of hydrogen peroxide (35% solution, 0.41mol) was added to a
solution of 5-ethyl-2-methyl-pyridine (104-90-5, 21.76 mL, 0.17 mol)
in glacial acetic acid (200 mL) and reﬂuxed for 16 h (depicted in step c
of Scheme 1). After evaporation of the majority of the solvent, the
reaction mixture was neutralized with NaOH and Na2CO3 and the
starting material was retrieved by extraction with petroleum ether.
5-Ethyl-2-methyl-pyridine-N-oxide was extracted from the aqueous
phase with CHCl3, dried over Na2SO4 and after removal of the solvent
obtained as a bright yellow liquid in 99% yield. 1H NMR (500 MHz,
CDCl3): δ = 8.14–8.09 (m, H-6), 7.12 (d, 3J(H,H) = 7.9 Hz, H-3),
7.00 (dd, 4J(H,H) = 1.3 Hz, 3J(H,H) = 7.9 Hz, H-4), 2.55 (q, 3J(H,H) =
7.7 Hz, 2H, CH2CH3), 2,48 (s, 3H, CH3), 1.20 (t, 3J(H,H) = 7.7 Hz, 3H,
CH2CH3).
2.2.4. 5-Ethylpyridin-2-yl-methyl acetate
As depicted in step d of Scheme1, a solution of the 5-ethyl-2-methyl-
pyridine-N-oxide, obtained in Section 2.2.5 (22.28 g, 0.16 mol), and
acetic anhydride (28 mL, 0.23 mol) in glacial acetic acid (7 mL) was
reﬂuxed for 3 h, put on ice, neutralized, extracted with methylene
chloride. After removal of the solvent, the extract was dissolved in
diethyl ether, washed with a saturated solution of Na2CO3 and dried
over Na2SO4 to give the product in 85% yield. 1H NMR (500 MHz,
CDCl3): δ = 8.42 (d, 4J(H,H) = 2.1 Hz, H-6), 7.50 (dd, 4J(H,H) =
2.2 Hz, 3J(H,H) = 7.9 Hz, H-4), 7.24 (d, 3J(H,H) = 7.9 Hz, H-3), 5.16 (s,
2H, H-7), 2.63 (q, 3J(H,H) = 7.6 Hz, 2H, CH2CH3), 2.11 (s, 3H, COCH3),
1.22 (t, 3J(H,H) = 7.6 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3):
δ = 170.79 (C_O), 153.04 (C-2), 149.35 (C-6), 138.70 (C-5), 136.11
(C-4), 121.89 (C-3), 66.98 (CH2–OAc), 25.89 (CH2CH3), 21.01 (COCH3),
15.36 (CH2CH3).
2.2.5. 5-Ethylpyridin-2-yl-methanol
As depicted in step e of Scheme 1, 5-ethylpyridin-2-yl-methyl
acetate (24.29 g, 0.14 mol) was dissolved in tetrahydrofuran (THF)
and reﬂuxed with an aqueous solution of NaOH (8.1 g, 0.20 mol) for
5 h. The reaction mixture was reboiled on activated charcoal and was
neutralized with glacial acetic acid and ﬁltered. After concentration
of the crude product under reduced pressure, it was dissolved in a
saturated solution of NaHCO3, extracted with diethyl ether and dried
Scheme 1. Synthetic routes for the pyrimidinylhydrazones 1, 2 and 3 starting from commercially available 4,6-dichloropyrimidine (1193-21-1) and 5-ethyl-2-methyl-pyridine
(104-90-5). Reaction conditions were as follows a) NaH, methanol,−10 °C to RT; b) N2H4, methanol, 65 °C; c) H2O2, glacial acetic acid, 120 °C; d) acetic anhydride, glacial acetic
acid, 120 °C; e) NaOH, THF, 70 °C; f) freshly prepared MnO2, CHCl3, ultrasound, 50 °C; g) catalytic acetic acid, ethanol, 80 °C.
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NMR (500 MHz, CDCl3): δ= 8.32 (d, 4J(H,H) = 1.9 Hz, H-6), 7.48 (dd,
4J(H,H) = 2.2 Hz, 3J(H,H) = 7.9 Hz, H-4), 7.20 (d, 3J(H,H) = 7.9 Hz,
H-3), 4.70 (s, 2H, CH2OH), 2.60 (q, 3J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.20
(t, 3J(H,H) = 7.6 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3): δ =
157.10 (C-5), 148.12 (C-6), 137.99 (C-2), 136.34 (C-4), 120.55 (C-3),
64.29 (CH2OH), 25.81 (CH2CH3), 15.40 (CH2CH3).
2.2.6. 5-Ethylpicolinaldehyde
As depicted in step f of Scheme 1, MnO2 was prepared freshly by
simultaneously adding a solution of MnSO4 hydrate (14.5 g, 0.09 mol
in 25 mL water) and NaOH (7.6 g, 2.21 mol in 20 mL water) to a
warm solution of KMnO4 (15.5 g, 0.10 mol in 100 mL water), reﬂuxing
the mixture for 6 h, ﬁltered and dried under reduced pressure.
5-Ethylpyridin-2-yl-methanol (12.82 g, 93.4 mmol) was dissolved in
chloroform and given to the dried MnO2 (16.24 g, 186.8 mmol). The
mixture was reﬂuxed in an ultrasonic bath for 5 days, ﬁltered and
puriﬁed with column chromatography using a mixture petroleum
ether and ethyl acetate (4:1) on silica gel to give the product as a bright
yellow liquid in 61% yield. 1H NMR (500MHz, CDCl3): δ=10.03 (s, 1H,
CHO), 8.60 (d, 4J(H,H) = 1.9 Hz, H-6), 7.87 (d, 3J(H,H) = 8.0 Hz, H-3),
7.70–7.63 (m, H-4), 2.73 (q, 3J(H,H) = 7.6 Hz, 2H, CH2CH3), 1.28
(t, 3J(H,H) = 7.6 Hz, 3H, CH2CH3). 13C NMR (126 MHz, CDCl3): δ =
193.30 (CHO), 151.06 (C-2), 150.18 (C-6), 144.67 (C-5), 136.28 (C-4),
121.72 (C-3), 26.43 (CH2CH3), 15.02 (CH2CH3).
2.2.7. Pyrimidinylhydrazones: 1, 2 and 3
The three Schiff bases 1, 2 and 3 were obtained by adding an
ethanolic solution of the hydrazinyl component to the solution of the
keto component in equimolar amounts (step g of Scheme 1), reﬂuxing
the mixture in the presence of catalytic amounts of acetic acid and
recrystallization from aqueous ethanol.
2.2.7.1. 4′-Methoxy-6′-(2-(pyridin-2-ylmethylene)hydrazinyl)pyrimidine
(1). The reaction of 2-pyridinecarboxaldehyde (191.1 mg, 1.78 mmol)
with 4-hydrazinyl-6-methoxypyrimidine (250mg, 1.78mmol) resulted
in bright rosy crystals of the product in 72% yield (293 mg, 1.28 mmol).
1H NMR (300MHz, CDCl3): δ=8.78 (bs, NH), 8.60 (d, 3J(H,H)= 4.8 Hz,
H-6), 8.38 (d, 5J(H,H) = 0.6 Hz, H-2′), 8.00 (d, 3J(H,H) = 8.0 Hz, H-3),
7.93 (s, 1H, C_NH), 7.75 (t, 3J(H,H) = 7.3 Hz, H-4), 6.63 (d, 5J(H,
H) = 0.7 Hz, H-5′), 3.99 (s, 3H, OCH3). 13C NMR (126 MHz, DMSO-d6):
δ = 170.00 (C-4′), 162.78 (C-6′), 157.77 (C-2), 153.47 (C-2), 149.28
(C-6), 142.77 (HC_N), 136.59 (C-4), 123.62 (C-5), 119.44 (C-3), 85.38
(C-5′), 53.54 (OCH3). ESI-MS: m/z calcd. for [M]: 229.0964. Found:230.0979 for [M + H]+, 252.0798 for [M + Na]+. Anal. calcd. for
C11H11N5O × 0.75 H2O: C, 54.43; H, 5.19; N, 28.85. Found: C, 54.36; H,
4.49; N, 28.94.
2.2.7.2. 4′-[2-[(5-Ethylpyridin-2-yl)methylidene]hydrazin-1-yl]-6′-
methoxypyrimidine (2). The reaction of 5-ethylpicolinaldehyde
(241.1 mg, 1.78 mmol) with 4-hydrazinyl-6-methoxypyrimidine
(250 mg, 1.78 mmol) resulted in bright rosy crystals of the product in
63% yield (288.7 mg, 1.12 mmol). 1H NMR (500 MHz, DMSO-d6): δ=
11.45 (s, 1H, NH), 8.43 (d, 4J(H,H) = 1.6 Hz, H-6), 8.33 (d, 5J(H,H) =
0.9 Hz, H-2′), 8.12 (s, C_NH), 7.93 (d, 3J(H,H) = 8.1 Hz, H-3), 7.68
(dd, 4J(H,H) = 2.1 Hz, 3J(H,H) = 8.2 Hz, H-4), 6.49 (d, 5J(H,H) =
0.6 Hz, H-5′), 3.89 (s, 3H, OCH3), 2.64 (q, 3J(H,H) = 7.6 Hz, 2H,
CH2CH3), 1.20 (t, 3J(H,H) = 7.6 Hz, 3H, CH2CH3). 13C NMR (126 MHz,
DMSO-d6): δ = 169.96 (C-6′), 162.78 (C-4′), 157.74 (C-2′), 151.22
(C-2), 148.73 (C-6), 142.91 (HC_N), 139.16 (C-5), 135.87 (C-4),
119.11(C-3), 85.26 (C-5′), 53.50 (OCH3), 25.15 (CH2CH3), 15.08
(CH2CH3). ESI-MS: m/z calcd. for [M]: 257.1277. Found: 258.1272
for [M + H]+, 280.1074 for [M + Na]+. Anal. calcd. for C13H15N5O:
C, 60.69; H, 5.88; N, 27.22. Found: C, 60.32; H, 5.76; N, 27.28.
2.2.7.3. 4′-Methoxy-6′-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)
pyrimidine (3, VP035). The reaction of 2-acetylpyridine (0.2 mL,
1.78 mmol) with 4-hydrazinyl-6-methoxypyrimidine (250 mg,
1.78 mmol) resulted in bright rosy crystals of the product in 79%
yield (342 mg, 1.41 mmol). 1H NMR (500 MHz, DMSO-d6): δ =
10.43 (s, 1H, NH), 8.57 (ddd, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.7 Hz,
3J(H,H) = 4.8 Hz, H-6), 8.37 (d, 5J(H,H) = 0.9 Hz, H-2′), 8.15 (dt,
5J(H,H) = 0.9 Hz, 3J(H,H) = 8.1 Hz, H-3), 7.85–7.75 (m, H-4), 7.35
(ddd, 4J(H,H) = 1.1 Hz, 3J(H,H) = 4.8 Hz, 3J(H,H) = 7.4 Hz, 1H, H-5),
6.57 (d, 5J(H,H) = 0.9 Hz, 1H, H-5′), 3.89 (s, 3H, OCH3), 2.40 (s, 3H,
C_NCH3). 13C NMR (126 MHz, DMSO-d6): δ = 170.04 (C-4′),
163.51(C-6′), 157.53 (C-2′), 155.24 (C-2), 148.42 (C-6), 147.91
(C_N), 136.44 (C-4), 123.40 (C-5), 119.93 (C-3), 86.10 (C-5′), 53.50
(OCH3), 11.76 (C_NCH3). ESI-MS: m/z calcd. for [M]: 243.1120.
Found: 244.1128 for [M + H]+, 266.0953 for [M + Na]+. Anal. calcd.
for C12H13N5O × 0.5 H2O: C, 57.13; H, 5.59; N, 27.76. Found: C, 57.23;
H, 5.46; N, 27.09.
2.3. Determination of relative lipophilicity by HPLC
HPLC–MSMS measurements were run on an AB Sciex 3200 QTrap
tandem mass spectrometer equipped with TurboV ion source. The
injected mixture (5 μL) contained 1, 2, 3 and uracil at a concentration
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the Q1/Q3 transitions were as follows: (1) 230/105 and 230/93;
(2) 258/133 and 258/121; (3) 244/227 and 244/186; (uracil) 113/96
and 113/70. The source parameters were as follows: dwell time:
200 ms; collision energy: 25 eV; IS (spray voltage): 5000 V; source
temperature: 450 °C; curtain gas: 25 instrument unit; GS1: 40
instrument unit; GS2: 40 instrument unit. A Perkin Elmer Series
200 microLC system (consisting of a binary pump, an autosampler
and a column oven) was used for separation. Gemini C18 110A
150 × 4.6 mm, 5 μm was used at 40 °C. The mobile phases were: A:
20 mM ammonium formate at pH = 10 adjusted by ammonia
(pH = 10 was selected based on the log D versus pH curve. At pH =
10, the compounds are present in neutral form, see Section 3.3); B:
methanol. Flow rate was 1 mL/min. The retention times of the com-
pounds were measured at 45, 50, 55, 60 and 65% methanol for the
accurate determination of log k (retention factor). Data acquisition
was stopped after the elution of the last sample. A 15 minute
equilibration step was used prior to the start of the runs at each
solvent composition.
The reduced retention time was calculated using the following
equation: k = (t0− t) / t0. Uracil was used for the exact determination
of t0. The retention time of uracil was 2.2 min at each solvent compo-
sition. The log k values of the different eluent composition runs were
expressed as the function of the methanol content of the eluent, and
extrapolated to pure water for the determination of log Kw.2.4. UV–Vis spectrophotometry
The pH-metric measurements for determination of the exact
concentrations of HCl and KOH stock solutions used for the spectro-
photometric titrations were carried out at 25.0 ± 0.1 °C in aqueous
solutions containing 0.5% (v/v) DMSO and at an ionic strength
of 0.20 M KCl in order to keep the activity coefﬁcients constant. All
the titrations were performed with carbonate-free KOH solutions of
known concentration (0.10 M) in the presence of 0.1 M KCl. An
Orion 710A pH-meter equipped with aMetrohm combined electrode
(type 6.0234.100) and aMetrohm 665 Dosimat burette were used for
the pH-metric titrations. The electrode system was calibrated to the
pH = − log[H+] scale by means of blank titrations (strong acid vs.
strong base; HCl vs. KOH) according to the method suggested by
Irving et al. [29]. The average water ionization constant, pKwater, is
13.76 ± 0.01 at 25 °C, which corresponds well to the literature data
[30]. Samples were deoxygenated by bubbling puriﬁed argon for ca.
10 min prior to the measurements and argon was also passed over
the solutions during further titrations.
A Hewlett Packard 8452A diode array spectrophotometer was used
to record the UV–Vis spectra in the 200–800 nm interval. The path
length was 1 cm. The spectrophotometric titrations were performed
on samples of ligand 3 alone or with Fe(III) or Cu(II). The concentration
of the ligand was usually 0.05 mM and the metal-to-ligand ratios were
1:1 and 1:2 over the pH range between 2 and 11.5 at an ionic strength
of 0.20 M (KCl) at 25.0 ± 0.1 °C. The initial volume of the samples was
10.00 mL. Measurements for 1:1 ligand‐to-Fe(III) system were also
carried out by preparing individual samples in which KCl was
partially or completely replaced by HCl. pH values, varying in the
range ca. 0.7–2.0, were calculated from the HCl content.
Protonation constants of ligand 3, the stability constants of its
metal complexes and the individual spectra of the species were
calculated by the computer program PSEQUAD [31] and literature
data were used for Fe(III) hydroxido species [32]. β (MpLqHr) is
deﬁned for the general equilibrium pM + qL + rH ⇌ MpLqHr as β
(MpLqHr) = [MpLqHr] / [M]p[L]q[H]r where M denotes the metal ion
and L the completely deprotonated ligand. The calculations were
always made from the experimental titration data measured in the
absence of any precipitate in the solution.2.5. Electrochemical studies
Cyclic voltammograms of the Fe(III) and Cu(II) complexes were de-
termined at 25.0± 0.1 °C in 90% (v/v) DMSO-water solution containing
1.0 mM metal ion or 1 mM ligand 3 while the metal-to-ligand ratio
was varied between 1:1 and 1:3. Ionic strength was 10 mM (TBACl).
Measurements were performed on a conventional three-electrode
system under argon atmosphere and a PC controlled Electrochemical
Measurement System (EF 451). Samples were purged for 15 min with
argon before recording the cyclic voltammograms. A glassy carbon
electrode was used as the working electrode, a platinum electrode as
the auxiliary electrode and Ag/AgCl/KCl (1 M) as reference electrode.
Electrochemical potentials were converted into the normal hydro-
gen electrode (NHE) scale by adding 0.236 V [33]. The electrochemical
system was calibrated with a solution of ferrocene in 90% (v/v)
DMSO-water (E1/2 = +0.428 ± 0.012 V vs. Ag/AgCl/KCl (1 M) in our
setup). Redox potentials were obtained at 100 mV/s scan rate in the
range of−1.2 to +1.0 V.
2.6. Oxidation of ascorbic acid (ASC) and glutathione (GSH)
Oxidation of ASC and GSH by the copper(II) and iron(III) complexes
of ligand 3 was studied by UV–Vis spectrophotometry using a Hewlett
Packard 8452A diode array spectrophotometer. A special, tightly closed
tandem cuvette (Hellma Tandem Cell, 238-QS, path length: 1 cm) was
used and the reactants were separated until the reaction was triggered.
Both isolated pockets of the cuvette were completely deoxygenated by
bubbling a stream of argon for 10 min before mixing the reactants.
Spectrawere recorded before and immediately aftermixing, and chang-
es were followed for maximum of 90 min. One of the isolated pockets
contained the reducing agent (ASC or GSH) at ten times higher concen-
trations than that of the metal ions. The other pocket contained the
metal ions (Cu(II): 25 μM; Fe(III): 50 μM) and ligand 3 at 1:1 metal-
to-ligand ratio. The pH of the solutions was adjusted to 7.40 (copper
complexes) or 5.45 (iron complexes) by 50 mM HEPES or MES buffers,
respectively, and an ionic strength of 0.1 M (KCl) was applied at
25.0 ± 0.1 °C. At the end of the measurements 30% H2O2 (50 μL) was
added to the samples (1.4 mL).
2.7. Establishment of transgenic ABCB1 expressing Madin–Darby canine
kidney II (MDCKII) cell line
MDCKII-ABCB1 cell line stably expressing the human wild-type
MDR1/ABCB1 was established by the Sleeping Beauty transposon-
based gene delivery system, using the 100× hyperactive SB transposase
[34]. MDCKII canine kidney cells were cotransfected with the SB
transposon vector containing the wild-type human MDR1 cDNA
[35] and the SB transposase vector construct, using the Lipofectamine
2000 reagent (Life Technologies) in accordancewith themanufacturer's
instructions. Brieﬂy, 3 × 105 cells were seeded in 6-well-plates; 24 h
later the cells were transfected with 2 μg vector DNA per well in a
10:1 ratio for the SB transposon and transposase constructs. 48 h after
transfection transgene positive cells were sorted by ﬂow cytometry
(FACS Aria High Speed Cell Sorter, Beckton-Dickinson) based on the
cell surface expression of wild-type and mutant MDR1/ABCB1. Protein
expression was measured by antibody labeling using the human
MDR1/ABCB1 speciﬁc monoclonal antibody MRK16 (Abnova). To ob-
tain homogenous transgene positive cell population, sorting procedure
was repeated 4 times in 2-week intervals.
2.8. Vector constructs
Sleeping Beauty (SB) transposon vector carrying the wild-type
humanMDR1 cDNAwas constructed as follows. The SB transposon vec-
tor containing the cDNAs of EGFP and the puromycin resistance gene
(PURO) in separate transcription cassettes, each driven by CAG
Table 1
Characterization of the relative lipophilicity of compounds 1, 2 and 3. Calculations were
performed with MarvinSketch 5.9.0 (logD7.4) [48]; log Kw values were obtained by
HPLC–MSMS.
1 2 3
logD7.4 2.36 3.32 1.92
log Kw 2.42 3.49 2.67
22 V.F.S. Pape et al. / Journal of Inorganic Biochemistry 144 (2015) 18–30promoter, was kindly provided by Dr. Tamás István Orbán (Hungari-
an Academyof Sciences, Budapest, Hungary) [36]. Full-lengthwild-type
MDR1 cDNA was ampliﬁed by PCR from pAcUW-LMDR1 vector [37]
with the following primers: 5′-TAGAATACCGGTAGGTCGGAATGGATCT
TGAA-3′ and 5′-AGTGATGGATCCAACATCTCATACAGTCAGAG-3′ con-
taining AgeI and BamHI restriction sites, respectively. The digested
PCR product was cloned into the SB-EGFP-PURO transposon vector be-
tween the AgeI and BclI restriction sites, replacing EGFP, resulting in SB-
MDR1-PURO vector.
2.9. Cell culture
The human ovarian carcinoma cell lines A2780 and the doxorubicin
selected multidrug resistant counterpart A2780adr were obtained from
ECACC, UK (A2780: No. 93112519, A2780adr: No. 93112520), and
cultivated in RPMI (Sigma Aldrich, Germany) supplemented with
10% fetal bovine serum and 50 units/mL penicillin and streptomycin
(Sigma Aldrich, Germany). The human uterine sarcoma cell lines
MES-SA and the doxorubicin selected MES-SA-Dx5 were obtained
from ATCC (MES-SA: No. CRL-1976™, MES-SA-Dx5: No. CRL-1977™)
and cultivated in Dulbecco's Modiﬁed Eagle Medium (DMEM,
SigmaAldrich, Hungary). The human cervix carcinoma cell line KB-3-1
and the vinblastine selected KB-v1 (kind gifts from Dr. Michael M.
Gottesman, National Institutes of Health) were cultivated in DMEM.
The phenotype of the resistant cells was veriﬁed using cytotoxicity
assays (not shown). MDCK II and the Pgp transfected MDCK-B1 were
cultured in DMEM. DMEM media (SigmaAldrich, Hungary) were
supplemented with 10% fetal bovine serum, 5 mmol/L glutamine,
and 50 units/mL penicillin and streptomycin (Life Technologies).
All cell lines were cultivated at 37 °C, 5% CO2.
2.10. MTT viability assay
MTT viability assays were performed as described earlier with
minor modiﬁcations [38,39]. Brieﬂy, cells were seeded into 96-well
tissue culture plates (Sarstedt, Newton, USA/Orange, Braine-l'Alleud,
Belgium) in the appropriate density evaluated for each cell line (5000
cells per well for MES-SA-Dx5 and KB-3-1/v1 cells, 10,000 cells per
well for A2780 cells) and allowed to attach for 12 h. Test compounds
were added to achieve the requiredﬁnal concentration in a ﬁnal volume
of 200 μL per well. After an incubation period of 72 h, the supernatant
was removed and fresh medium supplemented with the MTT reagent
(0.083mg/mL) was added. Incubation withMTT at 37 °Cwas terminat-
ed after 1 h by removing the supernatants and lysing the cells with
100 μL DMSO per well. Viability of the cells was measured spectropho-
tometrically by absorbance at 540 nmusing either a Perkin Elmer Victor
X3 or a BMG POLARstar microplate reader. Data was background
corrected by subtraction of the signal obtained from unstained cell
lysates and normalized to untreated cells. Curves were ﬁtted by Prism
software [40] using the sigmoidal dose–response model (comparing
variable and ﬁxed slopes). Curve ﬁt statistics were used to determine
the concentration of test compound that resulted in 50% toxicity (IC50).
2.11. ROS determination using DCFDA
Measurements were performed as reported in the literature with
modiﬁcations [41–43]. After harvesting and washing with phosphate
buffered saline (PBS), cells were incubated with 10 μM DCFDA in a
water bath shaker at 37 °C for 30 min in a density of 3 Mio cells/mL.
After washing with PBS cells were seeded to 96 well plates in PBS in a
density of 20,000 cells/well. Basal ﬂuorescence was measured; after
addition of the test compounds in different concentrations samples
were measured in time intervals of 10 min. DCFDA solution in buffer
was used as a cell free control to test for interaction of the test com-
pounds with DCFDA. Data was analyzed as fold change of ﬂuorescence
compared to the basal levels.3. Results and discussion
3.1. Synthesis
As depicted in Scheme 1, the pyrimidinylhydrazones 1 to 3 were
prepared by reacting 4-hydrazinyl-6-methoxypyrimidine (derived
from4,6-dichloropyrimidine)with equimolar amounts of the respective
keto component undermild acidic conditions.While compound1 serves
as the non-alkylated core structure, 2 possesses an ethyl group as
substituent in the aromatic ring and 3 has a methyl group at the imino
carbon. 5-Ethylpicolinaldehyde used for the synthesis of 2was prepared
following the method patented by Seydel et al. in a slightly modiﬁed
manner [15]. After formation of the N-oxide from 5-ethyl-2-methyl-
pyridine using hydrogen peroxide in glacial acetic acid, followed by
alkaline reconditioning, an acetoxy group was introduced using acetic
anhydride, glacial acetic acid to provide 5-ethylpyridin-2-yl-methyl
acetate. The cleavage of the ester to the corresponding alcohol was
carried out in THF, as the suggested conditions using ethanol as a
solvent provided the ethyl ether instead. The oxidation to the desired
aldehyde required a long time; and reﬂux with freshly prepared MnO2
under ultrasoundwas found to be an efﬁcient oxidizingmethod. Several
other methods including commercially available MnO2 [15], the
application of SeO2 and tert-butyl hydroperoxide [44], or the attempt
to directly oxidize the 5-ethyl-2-methyl-pyridine [45–47] were not
successful. With the help of the modiﬁcations in the ﬁrst and in the
last steps of the original approach, the yield could be increased from
the reported 18% to 40%.
Physico-chemical properties are known to inﬂuence pharmacoki-
netics and pharmacodynamics; therefore we were interested in the
lipophilicity of the three compounds. Since the lipophilicity of the
compounds was too high to allow the exact determination of logD7.4
values by the traditional shake ﬂask method in n-octanol/buffered aque-
ous solution (1:1), logD7.4 values were estimated using MarvinSketch
[48] and the relative lipophilicity of the compounds was determined
using HPLC. This method is commonly used for the determination
of log Kw (log P) [49]. We used an isocratic method to measure the
retention times of the neutral forms of the compounds as a function
of the organic composition of the eluent. Results of ﬁve different eluent
compositions (summarized in Supplementary Table A1) were used for
the accurate determination of the log k values as described in the
Materials and methods section. Since in this setup the retention coefﬁ-
cients of the three analytes show linear correlation with the volume
fractions of the organic solvent in the binary eluent, the relative lipophi-
licity of the compounds was determined using the linear solvent
strength model [49]. The resulting log Kw values are shown in Table 1.
3.2. Characterizing the in vitro antiproliferative activity of compounds
1 to 3
The cytotoxic potency of pyrimidinylhydrazones 1 to 3 was
investigated in a diverse panel of cancer cell lines including A2780
(ovarian carcinoma cells), KB-3-1 (cervix carcinoma) and MES-SA
(uterine sarcoma). To test the ability of the newly synthesized
compounds to overcome drug resistance, resistant derivatives of
the cell lines (A2780adr, KB-v1 andMES-SA-Dx5) were also included
in the study. Resistance of these cell lines is primarily mediated by the
overexpression of Pgp, which efﬂuxes structurally and mechanistically
Table 2
Cytotoxicity of the synthesized pyrimidinylhydrazonesmeasuredwithMTT viability assay
after 72 h of incubation. Values represent the mean ± standard deviation of IC50 values
(μM) obtained in at least three independent experiments.
IC50 (μM) ± SD 1 2 3
A2780 1.69 ± 0.60 1.31 ± 0.26 0.14 ± 0.05
A2780adr 1.97 ± 0.11 0.64 ± 0.14 0.03 ± 0.01
KB-3-1 1.96 ± 0.43 1.23 ± 0.04 0.35 ± 0.07
KB-v1 2.84 ± 0.60 1.58 ± 0.33 0.51 ± 0.14
MES-SA 2.84 ± 0.32 1.39 ± 0.32 0.31 ± 0.15
MES-SA-Dx5 2.54 ± 0.98 1.06 ± 0.27 0.13 ± 0.07
MDCK 6.30 ± 2.21 1.84 ± 0.97 0.51 ± 0.48
MDCK-ABCB1 3.55 ± 0.64 1.25 ± 0.74 0.29 ± 0.03
Fig. 1.UV–Vis absorption spectra of ligand 3 recorded at different pH values (a), calculated
individual absorption spectra (b) and concentration distribution curves for ligand species
(c). {cligand = 50 μM; t = 25.0 °C, I = 0.20 M (KCl)}.
Table 3
Overall protonation (logβ (HiL)) and proton dissociation constants (pKa) of
ligand 3 together with the λmax (nm) / ε (M−1 cm−1) values of the individual
species {t = 25.0 °C, I = 0.20 M (KCl)}.
logβ (HiL) pKa λmax (nm) ε (M−1 cm−1)
L – 312 20,198
HL+ 4.60 ± 0.01 4.60 (pK2) 282
356
10,650
17,520
H2L2+ 6.89 ± 0.01 2.29 (pK1) 276
344
10,560
23,340
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delineate the effect of Pgp on the toxicity of the compounds, we
included control MDCK-II and its drug resistant derivative MDCK-
II-ABCB1 engineered to overexpress cDNA-derived Pgp.
As summarized in Table 2, the three tested compounds proved to be
toxic in all investigated cell lines (with IC50 values of 0.03–6.30 μM)
regardless of their resistance status towards common cytostatic agents.
Toxicity of the compounds does not correlate with lipophilicity
(Table 1). Alkylation of 1 resulted in increased toxicity in all eight
investigated cell lines. Introduction of a methyl at the imino carbon,
as in 3 increases toxicity to a higher extent as compared to the introduc-
tion of an ethyl group at the aromatic ring as in compound 2.
3.3. Proton dissociation processes of ligand 3
Since the physico-chemical properties of a potential chemothera-
peutic agent have a basic inﬂuence on its pharmacokinetics and metal
binding abilities, a detailed study on the proton dissociation processes
of the most promising compound 3 was performed. For this purpose
UV–Vis spectrophotometric titrations were applied at a concentration
of 50 μM (in the presence of 0.5% (v/v) DMSO). The recorded pH-
dependent spectra (Fig. 1a) revealed two proton dissociation processes
at pH b 9; the calculated protonation constants (logβ(HiL)) and pKa
values are reported in Table 3. The spectra for the individual ligand
species in different protonation forms (H2L2+, HL+ and L) were
calculated by the deconvolution of UV–Vis spectra recorded at different
pH values (Fig. 1b). Titrations showed characteristic spectral changes in
the wavelength range 250–450 nm. Ligand 3 displays an intense
absorption band in all the protonation forms at 344 nm (H2L2+),
356 nm (HL+) and 312 nm (L), and less intense bands at 276 nm
(H2L2+) and 282 nm (HL+), which are assigned to n→ π* transitions.
The determined pKa values demonstrate that the proton dissociation pro-
cesses overlap and the neutral form L predominates in the physiological
pH range as illustrated in Fig. 1c. pK1 can most presumably be attributed
to the deprotonation of the pyrimidinium unit, while pK2 belongs
to the deprotonation of the pyridinium-N as shown in Scheme 2.
Deprotonation of the pyridinium moiety in the case of the α-N-
pyridyl thiosemicarbazones such as the drug Triapine was also shown
to result in similar spectral changes, namely a signiﬁcant shift of λmax
value from 402 nm to 368 nm [53]. The possible proton dissociation of
the hydrazinic=N–NH group of ligand 3 is likely to take place at higher
pH values (pH N 11) and therefore its pKa could not be determined
accurately with the applied method.
3.4. Complex formation processes of ligand 3 with Fe(III) and Cu(II)
The biological activity ofmetal binding compounds is oftenmodiﬁed
upon complex formation with metal ions [18,54]. Characterization of
metal binding ability (solution speciation), and the most plausible
chemical species formed in aqueous solution in the biologically relevant
pH range is amandatory prerequisite for understanding themechanism
of action of complexes. To this end, we determined the stoichiometryand stability of ligand 3 complexes formed with Fe(III) and Cu(II) in
aqueous solutions using UV–Vis spectrophotometry. The stoichiom-
etries of the metal complexes and the overall stability constants
furnishing the best ﬁts to the experimental data are listed in
Table 4. The appearance of well-deﬁned charge transfer (CT) bands
in the visible wavelength range of pH-dependent UV–Vis spectra
unequivocally showed complex formation with both metal ions
(Figs. 2 and 3). These CT bands overlap considerably with the ligand
bands, while the d–d bands are too weak to be detected under the
Scheme 2. Protonation and deprotonation equilibria for ligand 3.
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Fe(III), formation of the expected complexes [FeL]3+ and [FeL2]3+
could be veriﬁed. In these complexes the ligand coordinates most
probably via the (Npyridyl,Nhydrazone,Npyrimidyl) donor set. It is notewor-
thy that [FeL2]3+ is the predominant species at 1:2 metal-to-ligand
ratio in the physiologically relevant pH range (see inset of Fig. 2), al-
though the hydrolysis of themetal ion suppresses the complex formation
at pH N 8.5. Surprisingly, the development of CT bands that are character-
istic for Fe(II) complexes formed with ligands consisting of aromatic ni-
trogen donor atoms was also detected at pH N ~8.5 in the
510–610 nm wavelength range. Formation of minor amounts of
iron(II) complexes is possible at lower pH values aswell. The redox pro-
cess of the complex seems to be pH-dependent and much faster in the
basic pH range. Thus data collected at pH N 7.5 were not evaluated.
In order to compare the iron binding ability of ligand 3 with that
of other well-known iron chelators, the pM value (=− log [Fe(III)];
cL/cM = 10; cM = 1 μM) was calculated at physiological pH, using
the experimentally determined stability constants. For Fe(III) a pM
value of 17.6 was obtained, which is lower than those reported for the
naturally occurring iron binders such as human serum transferrin
(20.3) [55], desferrioxamine B (26.5) [56] or the chelator Deferiprone
(19.3) used to treat thalassemia major [57], but is higher than the pM
value of the thiosemicarbazone drug Triapine (15.7) [58]. Since higher
pM values imply that metal complex formation is more favored, these
results suggest that the studied pyrimidinylhydrazone forms less stable
complexes compared to the aforementioned chelators containingmain-
ly oxygen donor atoms. However, the Fe(III) binding ability of ligand 3
can exceed that of the tridentate α-N-pyridyl thiosemicarbazones
with a (Npyridyl,N,S−) binding mode at pH 7.4.
In the case of the Cu(II) ion, the formation of mono-ligand
complexes was expected due to the usual square planar geometry
of the Cu(II) coordination sphere, although the speciation model
was signiﬁcantly improved by the involvement of bis-ligand
[CuL2]2+ species (see Fig. A1). Deconvolution of the UV–Vis spectra
recorded in the Cu(II)–ligand 3 system yielded the formation con-
stants summarized in Table 4; individual spectra of the [CuLH]3+,
[CuL]2+ and [CuL2]2+ complexes are shown in Figs. 3b and A2.
Formation of the bis-ligand Cu(II) complex is not as pronounced as
in the case of Fe(III), which is reﬂected in the fact that its molar
fraction is only 0.52 at pH 7.4 (cL/cM= 2; cL = 50 μM), while the cor-
responding value is 0.80 in the case of [FeL2]3+ under the same con-
ditions. In the protonated complex [CuLH]3+ the ligand coordinates
most probably in a bidentate manner (i.e., (Npyridyl,Nhydrazone)); in
[CuL]2+ via the tridentate mode (Npyridyl,Nhydrazone,Npyrimidyl) was
suggested for pyridylhydrazones, which comprise similar binding
moieties [59]. In case of the [CuL2]2+ species a distorted octahedral
binding mode or a bidentate coordination of the ligands may be
possible, which is difﬁcult to ascertain without EPR studies.
In order to compare the Cu(II) and Fe(III) binding ability of ligand 3,
the pM value was also computed on the basis of the stability data
(conditions: pH = 7.40; cL/cM = 10 μM; cM = 1 μM) and a value
of 8.6 was obtained for Cu(II). Since Fe(III) tends to hydrolyze at physi-
ological pH, its hydroxido species were also taken into account and a
modiﬁed pM value (pM*) was determined for Fe(III), by calculating
the negative logarithm of the summed equilibrium concentrationsof the free metal ion and its hydroxido species (pM* = − log
([Fe] + Σ[Fep(OH)r])). pM* for Fe(III) was computed to be 9.5, which
is almost one order of magnitude higher than the pM of Cu(II). At an
acidic pH (5.45) pM* can be considered equal to pM, due to the lower
extent of hydrolysis, therefore values of 8.5 and 13.3 were computed
for the Cu(II) and Fe(III) complexes, respectively. These results indicate
that whereas ligand 3 forms stable complexes with both Fe(III) and
Cu(II), the unbound metal fraction is somewhat higher in the case of
Cu(II) showing the stronger Fe(III) binding ability of ligand 3 under
physiological conditions and in the slightly acidic pH range as well.
3.5. Effect of the metal ions on the toxicity of ligand 3
Having shown the strong metal binding ability of ligand 3 to Fe(III)
and Cu(II), experiments were designed to evaluate the impact of
metal ions on its toxicity. Ligand 3 was added to the parental MES-
SA cells and its resistant derivative MES-SA-Dx5 with increasing
concentrations of metal ions. The metal salts alone had no impact
on cell viability over a three day long incubation period; therefore
additive effects could be excluded. In MES-SA cells, coincubation of
3 with Fe(III) was found to reduce the ligand's cytotoxicity, while
the presence of Cu(II) had an opposite effect (Fig. 4). Interestingly,
the effects of both metal ions, namely the rescuing by iron and the
sensitization by copper was found to be signiﬁcantly attenuated in
MES-SA-Dx5 cell line, the drug resistant derivative of MES-SA.
Reduced activity of the free ligand in the presence of the iron
indicates that the toxicity may — at least in part — be explained by the
depletion of cellular iron levels. The differential sensitivity of the drug
resistant subline is reminiscent of the collateral sensitivity of MDR
cells [60]. The mechanisms underlying the paradoxical hypersensitivity
of resistant cells are not known. It has been suggested, but never shown,
that the metal homeostasis of MDR cells is altered as a result of Pgp
function. Lack of the protective effect of Fe(III) in the MDR subline
suggests that these cells cannot be rescued by excess iron — perhaps
due to the imbalanced iron homeostasis of MDR cells.
In follow up experiments the Cu(II) and Fe(III) complexes of
ligand 3 were prepared in situ by mixing the ligand with half- and
one equimolar concentrations of the metal ions. Using this setup a
constant molar ratio was ensured throughout the investigated con-
centration range (1 nM–250 μM). Results obtained in the presence
of increasing metal ion concentrations at a ﬁxed ligand-to-metal
molar ratio conﬁrmed the reduced toxicity of Fe(III) complexes
(not shown), while the effect of Cu(II) was less pronounced in that
setup as compared to the coincubation (Fig. 7).
3.6. Cyclic voltammetric studies of Fe(III) and Cu(II) complexes of ligand 3
Besides depletingmetal ions, the mechanism of toxicity of chelat-
ing compounds also relies on redox active complexes that may be
formed in the Fenton reaction [1,7,41]. To examine the redox proper-
ties of the iron and copper complexes of ligand 3, we performed
cyclic voltammetry (CV) studies and the measured formal potentials
were compared to those of Triapine and physiological reductants.
Illustrative voltammograms are shown in Fig. 5. Measurements
were performed in 90% (v/v) DMSO/H2O in the potential range
Table 4
Overall stability and stepwise constants of Fe(III) and Cu(II) complexes of ligand 3 together with the λmax (nm) / ε (M−1 cm−1) values of the individual species {t = 25.0 °C,
I = 0.20 M (KCl)}.
Fe(III) Cu(II)
n logβ λmax
(nm)
ε
(M−1 cm−1)
n logβ λmax (nm) ε
(M−1 cm−1)
[MLH]n+ – – – – 3 12.16 ± 0.09 342 16,640
[ML]n+ 3 15.69 ± 0.07 320
368
424
10,600
10,800
8600
2 7.39 ± 0.01 410 19,600
[ML2]n+ 3 21.71 ± 0.06 380
304
12,500
9200
2 12.35 ± 0.03 402 40,510
logK2 6.02 4.96
25V.F.S. Pape et al. / Journal of Inorganic Biochemistry 144 (2015) 18–30of −0.9 to +1.0 V against Ag/AgCl/KCl (1 M). Ligand 3 alone was
found to be redox-innocent in this range. It should be noted that
the ligand alone shows an irreversible process resulting in a cathodic
peak seen at ~−1.01 V vs. Ag/AgCl/KCl (1 M) (which corresponds
to−0.78 vs. NHE, Fig. A3). The complexes of both metal ions showed
redox activity. The redox potential of the formed complexes is large-
ly controlled by the donor atoms of the ligand that are present in the
ﬁrst coordination shell. The addition of the chelating agent signiﬁ-
cantly changed the peak positions in comparison to those of the
aqua complexes. The detected redox processes for the Fe(III)/Fe(II)
and Cu(II)/Cu(I) couples were found to be quasi reversible under
the applied conditions in all cases (for a detailed analysis of CV
data see Table A2).
Addition of ligand 3 to Fe(III) results in the formation of a metal
complex and the appearance of a new set of peaks in the voltammograms
at ~+0.68 V vs. NHE as calculated from themeasured data represented in
Fig. 5a. Upon complexation the formal potential increased by 0.31 V;
the intensity of the aqua ion peaks decreased, while that of the metal
complex increased with increasing ligand excess. The positive shift
of the formal potentials due to the coordination by the ligand via
(Npyridyl,Nhydrazone,Npyrimidyl) donor set indicates a preference for
the lower oxidation state, as in the case of other well-known ligands
consisting of aromatic nitrogen donor atoms such as 2,2′-bipyridyl
or 1,10-phenanthroline. This can be a possible explanation for the
reduction of Fe(III) complexes in the basic pH range (vide supra).
The formal potential of the complexed Fe(III)/Fe(II) redox couple
is signiﬁcantly higher (~+0.69 vs. NHE) than that of other iron
chelators such as Triapine (+0.07 V vs. NHE) [58] or tris-hydroxamato
complexes (−0.43 V) [61] resulting in an easier reduction by
physiological reductants.
Ligand 3 also inﬂuences the redox potential of the Cu(II)/Cu(I) couple.
Addition of the ligand diminished the intensity of the aqua complex
peaks, while a new reduction peak appeared upon complexation.Fig. 2. UV–Vis absorption spectra recorded for the Fe(III)–ligand 3 system at various
pH values and at 1:2 metal-to-ligand ratio. Inset shows the pH-dependent absor-
bance values at 420 nm for the same system (●) and for the ligand alone (♦).
{cligand = 50 μM; t = 25.0 °C, I = 0.20 M (KCl)}.In case of the copper complexes, the formal potential was shifted
by 0.25 V to the negative direction, indicating the ligand preference
for themetal ion in the higher, +2 oxidation state. The formal potential
of the Cu(II)/Cu(I) in the case of ligand 3 (+0.36 V vs. NHE) is higher
than that of the biological reductants (glutathione, ascorbate [1,62]),
thus the reduction of this Cu(II) complex may lead to redox cycling
and the generation of ROS.
3.7. Reduction of complexes formed with ligand 3 by intracellular
reducing agents
In order to further investigate the potential of the copper and iron
complexes formed with ligand 3 to undergo intracellular redox
reactions, the ability of biologically relevant reducing agents such
as ascorbate (ASC) or glutathione (GSH) to reduce the complexes
was tested in in vitro assays. The redox processes were followed
spectrophotometrically under strictly anaerobic conditions via
monitoring the overlapping ligand and CT bands in the wavelength
range of 300–600 nm. Kinetic runs were performed at pH 7.40 in the
case of the copper complexes, while pH 5.45 was chosen for the ironFig. 3. UV–Vis absorption spectra recorded for the Cu(II)–ligand 3 system at various pH
values and at 1:1 metal-to-ligand ratio (a) and calculated individual absorption spectra
of the Cu(II) complexes (b). {cligand = 50 μM; t = 25.0 °C, I = 0.20 M (KCl)}.
Fig. 4. Toxicity of ligand 3 assessed in the presence of increasing concentrations of
FeCl3 (a) or CuCl2 (b) in MES-SA (open squares) and MES-SA-Dx5 (ﬁlled squares)
cells. IC50 values were obtained after 72 h incubation with the compounds, measured
by the MTT assay. Data represent the mean standard deviation obtained in 6 (a) and
3 (b) independent experiments.
Fig. 5. Cyclic voltammograms of iron (a) and copper (b) complexes of ligand 3 vs.
Ag/AgCl/KCl (1.0 M) {t = 25.0 °C, I = 0.01 M (TBACl) in 90% (v/v) DMSO/H2O
mixture, cL = 1.0 mM; 100 mV/s scan rate, glassy carbon working electrode}.
Data obtained with the ligand alone (dashed, gray) or at various M:L ratios (1:0 (dashed
dotted black), 1:1 (solid red), 1:2 (dotted blue) and 1:3 (solid green)) are shown.
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formation of the Fe(II) species in the Fe(III)–ligand 3 system in
the basic pH range (see Section 3.3). Oxidation of ASC yields dehydro-
L-ascorbic acid; the oxidized form of GSH is glutathione disulﬁde
(GSSG). Neither the reduced and oxidized form of ASC nor GSH absorbs
light at λ N ~310 nm [63], thus spectral changes above this wavelength
are characteristic only to the absorption of the metal complexes.
Oxidation of ASC or GSH is often monitored at their λmax values
(265 and 262 nm, respectively) [9,64], but since the studiedmetal com-
plexes, as well as the free ligand 3 absorb light strongly in the UV range,
the UV–Vis spectra were recorded between λ ~ 300 nm and 600 nm
upon addition of ASC and are shown in Fig. 6. No time dependent
spectral changes were observed (tmax = 75 min) in the case of the
Cu(II) complexes (Fig. 6a), which suggests that this metal complex
could not be reduced by ASC under the applied conditions.
We also monitored the spectral changes of the formed complexes
upon reduction by GSH (Fig. 6c). Glutathione is a predominant intracel-
lular reducing agent with a lower formal potential compared to that of
ASC. (The formal potential at pH 7.4 of the GSSG/GSH and the
dehydro-L-ascorbic acid/ASC redox pairs are −0.26 V and +0.05 V,
respectively [62,65].) In the case of copper a signiﬁcant decrease of the
absorbance was observed at the λmax value of the Cu(II) complex
(408 nm) during the redox reaction; while the absorbance value was
increased at the λmax of the free ligand (~310 nm), most probably as a
result of the decomposition of the generating instable Cu(I) complex.
These results suggest that the stronger reducing agent GSH is able to
reduce the Cu(II) complex. Addition of H2O2 regenerated the Cu(II)
complexes, suggesting that a reversible redox process can contribute
to the toxicity of the compound.
In line with the high redox potential of the Fe(III)–ligand 3 complex
(see Section 3.6), this complex was reduced by ASC (Fig. 6b); yet theredox reactionwas relatively slow.WhenH2O2was added to the sample
at the end of the kinetic run only negligible spectral changes were
observed even after 0.5 h, suggesting that the iron complex is not likely
to undergo intracellular redox cycling.
Surprisingly, ten-fold excess of GSH resulted in almost no changes in
the UV–Vis spectrum of the Fe(III)–ligand 3 system (Fig. 6b) within
90min, suggesting that the kinetic of the reduction is fairly slow. A sim-
ilar trend was observed in the reduction kinetics of vanadium com-
plexes by the two reducing agents [63,64]. Furthermore, the formal
potentials of both reducing agents are pH-dependent, which might
also explain the lack of GSH-induced reduction of the iron complex at
pH 5.45. Based on studies on the pHdependence of the redox potentials,
it can be estimated that at pH 5.45, the redox potential of GSH and ASC
are shifted by 116 mV and 52 mV, respectively [62,65,66].
Taken together, our results indicate that the Cu(II) complex of
ligand 3 has the potential to undergo redox-cycling reactions under
physiological conditions, whereas the iron complex is probably not
able to undergo intracellular redox cycling.
3.8. Involvement of ROS in the toxicity of 3
To evaluate the role of ROS production in the toxicity of 3, the cyto-
toxicity experiments were repeated in the presence of the antioxidant
NAC. Coincubation with NAC resulted in a signiﬁcant increase of
the IC50 values (Fig. 7), suggesting that ROS play a role in the toxicity
of ligand 3. Due to the relative redox potentials a direct reduction of
compound 3 by NAC is unlikely; therefore a more probable source of
Fig. 6. Time-dependent UV–Vis spectra of Cu(II)–ligand 3–ASC (a) and GSH (c), as well as Fe(III)–ligand 3–ASC (b) and GSH (d) system at 1:1:10 ratio. The dotted gray line denotes the
spectrum obtained upon addition of H2O2. {cCu(II) = 25 μM; cFe(III) = 50 μM; t= 25.0 °C, I = 0.1M (KCl); pH 7.40 (50 mMHEPES) for the Cu(II) and pH 5.45 (50mMMES) for the Fe(III)
complexes}.
27V.F.S. Pape et al. / Journal of Inorganic Biochemistry 144 (2015) 18–30ROS induction is the intracellular formation of redox active complexes
undergoing Fenton-like chemistry. In the next set of experiments
Cu(II) complexes of ligand 3 were coincubated at 1:1 and 1:2 metal-
to-ligand ratios with NAC and cytotoxicity was measured in MES-SA
and MES-SA-Dx5 cells. Since complexation with Fe(III) signiﬁcantly
attenuates the toxicity of ligand 3, the effect of NAC on the toxicity of
the iron complexes could not be reliably determined.Fig. 7. Effect of the antioxidant scavenger NAC on the toxicity of 3. A2780 (a) or A2780adr (b)
Dose response curves obtained for 3 alone (black circles) or in the presence of 1 mM (green cir
at least three independent experimentswith standarddeviation. Panel (c) depicts IC50values of
(ﬁlled columns) cells in presence or absence of 5 mM NAC. Asterisks indicate signiﬁcance as caAs expected, NAC diminished the toxicity of the Cu(II) complexes,
suggesting that ROS may, at least in part, be responsible for the toxicity
of the ligand and its metal complexes (Fig. 7c). Intriguingly, the
(relative) protective effect of the antioxidant appeared to be more
pronounced in drug resistant cells as compared to their sensitive
counterparts (compare A2780adr, Fig. 7b to A2780, Fig. 7a, and dx5
to MES-SA, Fig. 7c).cells were treated with increasing amounts of 3with or without the ROS scavenger NAC.
cles), 2.5 mM (red diamonds) and 5 mM (blue squares) of NAC are shown. Data represent
ligand 3 and its copper (II) complexes obtained inMESSA (open columns) andMESSA-Dx5
lculated from t-tests (*: p b 0.05, **: p b 0.005, ***: p b 0.0005).
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measured using the ROS-sensitive cell permeable dye DCFDA. MES-SA
and MES-SA-Dx5 cells were preincubated with DCFDA and the effect
of ligand 3 and its complexes on ﬂuorescence was evaluated following
an 80 minute-long incubation period. Fig. 8 summarizes the results
obtained with MES-SA cells (Dx5 cells yielded similar results; Fig. A4).
At 50 μM, ligand 3 did not induce an increase in ﬂuorescence. Complex-
ation with iron resulted in ROS production in the case of both metal-to-
ligand ratios used ([FeL]3+ and [FeL2]3+) (Fig. 8a). Addition of Cu(II)
resulting in 1:1 metal-to-ligand ratio (mostly [CuL]2+, see Fig. A2) in-
duced the formation of ROS, while the [CuL2]2+ complex was not
redox active (Fig. 8a). In all cases, ROS induced by the metal complexes
could be scavenged by the addition of NAC. A similar pattern was
observed at 100 μM ligand concentration (Fig. 8b). Unexpectedly,
addition of the ROS scavenger NAC to 100 μMof the [CuL]2+ complex
increased, rather than decreased ROS production. Since this effect
could also be observed in the cell free condition, we speculate
that the paradoxical effect of NAC is explained by the ability of the
complex to participate in redox cycling as a result of the reduction
by NAC (see also Figs. 5b, 6c). The Fenton-like reaction results in
increased ROS production, but direct oxidation of DCFH may alsoFig. 8. Characterization of intracellular ROS production with the DCFDA assay. ROS induction by
amount of Fe(III) (a) or Cu(II) (b). MES-SA cells (open columns) were loaded with DCFDA an
compounds. As a control the signal induced with 1.6 mM tert-butyl hydroperoxide is shown
the tested compounds). Fold change in ﬂuorescence represents the ratio of the measured ﬂuo
Values show the mean of ﬁve independent experiments performed in duplicates; error bars recontribute to the observed signal [67,68]. Induction of ROS by NAC
was only observed at 100 μM ligand concentration, which is between
300 and 1000 times higher than the IC50 values obtained in the
toxicity studies displayed in Fig. 7c. At [CuL]2+ ≤ 50 μM, addition of
NAC protects against the formation ROS (Fig. 8a), in line with the
protective effect of NAC against the toxicity of compound 3 even in
combination with copper (Fig. 7c).
3.9. Evaluation of the toxicity of ligand 3 in MDR cells
Chelators that bypass resistance mechanisms are promising
candidates for anticancer drug development [8,69]. ABC transporters
contribute signiﬁcantly to the multifactorial phenomenon of MDR
[70–72]. As a strategy to overcome Pgp-mediated MDR, several
inhibitors have been developed [73,74]. Despite promising in vitro
results, successful translation of MDR transporter inhibition to the
clinic remains elusive [75–77]. Hence there is an urgent need for
novel chemotherapeutics with marked and selective antitumor ac-
tivity, particularly those that can overcome resistance to established
therapies. Several chelators have been reported to overcome or even
exploit MDR [8,69]. The toxicity pattern of the newly synthesized50 μM or 100 μM ligand 3was evaluated in the presence of equimolar and half equimolar
d ﬂuorescence intensity was measured following 80 min incubation with the indicated
. Dotted columns represent the cell-free condition (the interaction between the dye and
rescence intensity to the basal intensity before treatment with the indicated compounds.
present standard deviation.
Fig. 9. Effect of Pgp-inhibition on the toxicity of ligand 3. A2780 and A2780adr (a) or
MES-SA and MES-SADx5 (b) cells were treated with increasing amounts of 3. Open
symbols represent the drug-sensitive parental lines; ﬁlled symbols represent the
Pgp-expressing MDR derivatives. The effect of the Pgp inhibitors WK-X-24 for
A2780adr, and TQ for MES-SADx5 is shown with gray symbols.
Fig. 10. Intracellular redox reactions involved in the redox cycling of metal ions. Green
arrows depict reactions catalyzed by the copper-containing superoxidedismutase enzyme
[41], the red arrow represents the Fenton reaction [1]; the blue arrows represent the redox
cycling of the metal ions, which can be activated by the reduction through antioxidants
such as glutathione or NAC.
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investigated cell lines regardless of their resistance status (Table 2), sug-
gests that these compounds are not susceptible to Pgp-mediated efﬂux.
Interestingly, compound 3 shows enhanced activity towards the Pgp
expressingMES-SA-Dx5 and A2780adr derivatives. Paradoxical toxicity
towards otherwise resistant cells was observed in the case of several
chelators, as for the thiosemicarbazone NSC73306 [69]. Intriguingly,
the toxicity of the so-called MDR-selective compounds is increased,
rather than attenuated by the activity of efﬂux transporters such as
Pgp [60,69,78]. To determine the role of Pgp in the increased sensitivity
of MDR cell lines to compound 3, cytotoxicity measurements were
repeated in the presence of the Pgp-inhibitor TQ or WK-X-24 (Fig. 9)
[73,74]. Inhibition of Pgp did not inﬂuence the toxicity of the com-
pounds, suggesting that the observed hypersensitivity of the cells is
linked to other factors than Pgp.4. Conclusions
There is a continuous demand for the development of novel types of
antitumor agents especially with the potential to overcome multidrug
resistance. In this work three new pyrimidinylhydrazone Schiff bases
were synthesized and characterized, and their antitumor potential and
putative mechanism of action were evaluated. The cytotoxicity of the
compounds was studied in a panel of human cancer cell lines and the
canineMDCK-ABCB1 that was explicitly engineered to evaluate the effect
of Pgp, the ATP-dependent pump responsible for the efﬂux of a broad
spectrum of cytotoxic agents. The three tested compounds proved to
be cytotoxic in the micro- to submicromolar range, regardless of the
resistance status of the cells. Methylation of the core structure at the
imine carbon resulted in the most active compound among the studied
derivatives (3), since it seemed to increase the toxicity to a higher extent
than the introduction of an ethyl-substituent in the pyridine-moiety.Due to themetal binding ability of ligand3, its biological activity is like-
ly to be mediated via the formation of complexes with essential metal
ions. Thehigh stability of the Fe(III) complex togetherwith aprotecting ef-
fect upon coincubationwith themetal ion suggests that themechanismof
actionmight be partlymediated by iron depletion. Stable complex forma-
tion was also observed with Cu(II). While the complexes of both metal
ions show redox activity in cyclic voltammetry measurements, only the
Cu(II) complex showed reversible redox cycling in biological relevant con-
ditions (GSH reduction followed by H2O2 oxidation). Intracellular redox
cycling ofmetal complexesmight result in ROS formation (Fig. 10). A sim-
ilar mechanism (“activation by reduction”) has been suggested to explain
the enhanced toxicity of other copper complexes compared to their free
ligands by Kowol et al. [41].
Protection from compound-induced cell death by coadministration
of the potent ROS scavenger NAC supports this theory. ROS production
induced by the metal complexes of ligand 3 was supported by the
ROS-sensitive DCFDA ﬂuorescence assay.Abbreviations
ABC ATP-binding cassette
APT attached proton test
ASC L-ascorbic acid
CT charge transfer
CV cyclic voltammetry
DCFDA 2′,7′-dichloroﬂuorescin diacetate
DMEM Dulbecco's Modiﬁed Eagle medium
EGFP enhanced green ﬂuorescent protein
ESI-MS electrospray ionization-mass spectrometry
GSH glutathione
GSSG glutathione disulﬁde
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
MDCK Madin–Darby canine kidney
MDR multidrug resistance
MES 2-(N-morpholino)ethanesulfonic acid
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
NAC N-acetylcysteine
PBS phosphate buffered saline
Pgp P-glycoprotein
ROS reactive oxygen species
RPMI Roswell Park Memorial Institute
RR ribonucleotide reductase
SB Sleeping Beauty
TBACl tetrabutylammonium chloride
THF tetrahydrofuran
TQ Tariquidar
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